Abstract: The invention provides pharmaceutical compositions of methylenediamine and methods thereof for treating various types of cancer (e.g., lung cancer, liver cancer, skin cancer, ovarian cancer, prostate cancer, breast cancer and blood cancer).

Abstract: The uses of guanidine hydrochloride as a drug for treating cancers/tumors. Guanidine hydrochloride can destroy the formation of hydrogen bonds by polar molecules on the surface of cancer cells and the macromolecules taken up, thereby demonstrating that guanidine hydrochloride can inhibit the uptake by cancer cells. The present invention provides new uses of guanidine hydrochloride in the treatment of subjects suffering from cancers/tumors and prevention of recurrence after cancer operation. The dose of guanidine hydrochloride administration is 10-35 mg/kg a day. The hydrochloride dose of the guanidine has a significant inhibitory effect on the uptake of DNA by cancer cells, which in turn can effectively inhibit the proliferation of cancer cells; besides, the inhibition rate of liver cancer tumors 9 days after the injection of guanidine hydrochloride drugs can reach 42%, and the inhibition rate of lung cancer tumors 7 days after the injection of guanidine hydrochloride drugs reach 56.8%.

Abstract: The uses of guanidine hydrochloride as a drug for treating cancers/tumors. Guanidine hydrochloride can destroy the formation of hydrogen bonds by polar molecules on the surface of cancer cells and the macromolecules taken up, thereby demonstrating that guanidine hydrochloride can inhibit the uptake by cancer cells. The present invention provides new uses of guanidine hydrochloride in the treatment of subjects suffering from cancers/tumors and prevention of recurrence after cancer operation. The dose of guanidine hydrochloride administration is 10-35 mg/kg a day. The hydrochloride dose of the guanidine has a significant inhibitory effect on the uptake of DNA by cancer cells, which in turn can effectively inhibit the proliferation of cancer cells; besides, the inhibition rate of liver cancer tumors 9 days after the injection of guanidine hydrochloride drugs can reach 42%, and the inhibition rate of lung cancer tumors 7 days after the injection of guanidine hydrochloride drugs reach 56.8%.

Abstract: This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. The mechanism of cancer cells uptake of large DNA fragment (larger than 30 bp) is endocytosis which does not occur in normal organ cells. We are the first to identify this difference and use the selectivity to deliver isotope P-32 to treat cancer. The DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the tumor cell's DNA through recombination, and then the isotope kills the tumor cells. Illustratively, a gene or a DNA fragment is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. Appropriate doses are provided to patients as part of a medical treatment method.

Abstract: This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. Linear DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the tumor cell's DNA through recombination, and then the isotope kills the tumor cells. Illustratively, a gene or a DNA fragment is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. The illustrative embodiment produces the compound/agent containing a DNA fragment and P-32 through use of conventional P-32 labeling techniques such as those employed in molecular biology experiments (for example experiments used to test gene expression and gene amplification potency). The same P-32 labeled DNA can be employed directly for cancer treatment through a novel medical treatment method.

Abstract: This invention provides a combination of a gene and isotope therapy that is applied to a cancerous tissue to selectively kill that associated cancer cells with minimal negative effects on surrounding non-cancerous cells. Functionally, the specific DNA fragments with labeled isotope are able to bind the tumor cells DNA through recombination, and then the isotope kills the tumor cells. A gene is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. Unlike traditional gene therapy, which employs a gene to express a protein, which can suppress the cancer cell growth or increase the sensitivity for radiation therapy or chemotherapy, the illustrative embodiment actually binds the radioactive substance via a gene.

Abstract: This invention provides a combination of a gene and isotope therapy that is applied to a cancerous tissue to selectively kill that associated cancer cells with minimal negative effects on surrounding non-cancerous cells. Functionally, the specific DNA fragments with labeled isotope are able to bind the tumor cells DNA through recombination, and then the isotope kills the tumor cells. A gene is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. Unlike traditional gene therapy, which employs a gene to express a protein, which can suppress the cancer cell growth or increase the sensitivity for radiation therapy or chemotherapy, the illustrative embodiment actually binds the radioactive substance via a gene.

Abstract: An instrument and method for determining the current blood glucose level of an individual by noninvasive measurement of the current electrical capacitance of the outer surface of the skin of such individual and comparing that current capacitance level to stored data of previously determined capacitance levels of the skin and their associated blood glucose levels of that individual for determining the blood glucose level associated with the currently determined capacitance level.